Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.47 |
| ▸ | CTSK | P43235 | 12/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CCR10 | P46092 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035629 | 0.90 | CTSS (0.44) | CTSSCTSKCTSLCTSBCCR10 | |
| SCHEMBL1082714 | 0.82 | CCR10 (0.64) | CCR10 | |
| SCHEMBL15496837 | 0.73 | P2RX3 (0.43) | CTSSCTSKPPARAPPARGPTPN1 | |
| SCHEMBL23860001 | 0.73 | ARG1 (0.49) | PPARAPPARGPTPN1ACE | |
| SCHEMBL1082633 | 0.73 | PPARA (0.42) | CCR10PPARAPPARGPTPN1ACE | |
| SCHEMBL23860004 | 0.73 | ARG1 (0.49) | PPARAPPARGPTPN1ACE | |
| SCHEMBL15496828 | 0.72 | PPARA (0.43) | CTSSCTSKPPARAPPARGPTPN1 | |
| SCHEMBL31649054 | 0.72 | AKT1 (0.49) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL21663695 | 0.72 | CTSS (0.63) | CTSSCTSKCTSLCTSBPPARA | |
| SCHEMBL28538006 | 0.72 | AKT1 (0.49) | CTSSCTSKCTSLCTSBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586748-B2 | 2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20110275800-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| EP-2276731-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | Boehringer Ingelheim International GmbH (DE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009126675-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275800-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | CCR10, CCR1, CCR4 | CTSS 3867/4885CTSK 4292/4885CTSL 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.